Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.35 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.35 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.35 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.35 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.35 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.35 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.35 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706919 | 0.83 | APLNR (0.49) | APLNRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL3126914 | 0.81 | CYP3A4 (0.58) | ALDH1A1TDP1CYP3A4HPGDKDM4E | |
| SCHEMBL17650515 | 0.76 | APLNR (0.41) | APLNRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL30786878 | 0.76 | APLNR (0.41) | APLNRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL6395292 | 0.74 | ALDH1A1 (0.50) | APLNRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL22602688 | 0.74 | APLNR (0.40) | APLNRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL3674074 | 0.73 | CA9 (0.50) | ALDH1A1TDP1CYP3A4HPGDCYP1A1 | |
| SCHEMBL30701949 | 0.73 | CA9 (0.50) | ALDH1A1TDP1CYP3A4HPGDCYP1A1 | |
| SCHEMBL30940602 | 0.73 | CA12 (0.52) | APLNRALDH1A1CYP3A4HPGDMIF | |
| SCHEMBL2143429 | 0.73 | ALDH1A1 (0.68) | APLNRALDH1A1TDP1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236965-B2 | Benzimidazole derivatives and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-08-07 | — | — | US | disclosed |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-07-02 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| EP-1467974-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOD CONSEILS RECH APPLIC (FR) | 2007-08-15 | — | — | EP | disclosed |
| US-20050049290-A1 | Benzimidazole derivatives and their use as gnrh antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 2005-03-03 | — | — | US | disclosed |
| EP-1467974-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (FR) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003053939-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-07-03 | — | — | WO | disclosed |
| WO-1979000166-A1 | CYANOCARBOXAMIDINES AND QUINAZOLINE PROCESS | BRISTOL MYERS CO (US) | 1979-04-05 | — | — | WO | disclosed |
| US-4138561-A | Cyanocarboxamidines and quinazoline process | BRISTOL-MYERS COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | GNRHR, FSHR, KISS1R | APLNR 2194/4885ALDH1A1 2294/4885TDP1 4048/4885 |
| US-20050049290-A1 | Benzimidazole derivatives and their use as gnrh antagonists | GNRHR, FSHR, KISS1R | APLNR 1852/4885ALDH1A1 3107/4885TDP1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.